GrafTech International Ltd. — 2014 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014. The filing was signed March 2, 2015. The requested “2014 Q4” period is covered within this annual filing; quarterly figures below are unaudited.
Business context
GrafTech manufactures graphite and carbon products through two segments: Industrial Materials (graphite electrodes, refractories and needle coke) and Engineered Solutions (specialty graphite, composites, electronics and other advanced materials). Industrial Materials accounted for about 77% of 2014 sales. The business faced weak steel-market conditions, price pressure and rationalization activity.
Key financial results
| Metric | 2014 | 2013 |
|---|---|---|
| Net sales | $1,085.3 million | $1,166.7 million |
| Gross profit / margin | $92.2 million / 8.5% | $139.1 million / 11.9% |
| Operating income (loss) | $(255.6) million | $(2.6) million |
| Net income (loss) | $(285.4) million | $(27.3) million |
| Diluted loss per share | $(2.10) | $(0.20) |
| Cash from operating activities | $120.9 million | $116.8 million |
| Capital expenditures | $85.0 million | $86.3 million |
- Revenue declined 7%. Industrial Materials sales fell 8% to $840.1 million, with electrode realized selling prices down about 10%, partly offset by higher electrode volumes. Engineered Solutions sales fell 5% to $245.2 million, mainly from consumer-electronics pricing and demand pressure.
- Operating loss included $197.2 million of impairments: $121.6 million for long-lived assets following the decision to exit isomolded products and $75.7 million of needle-coke goodwill impairment. The company also recorded $62.8 million of rationalization and related charges, as summarized in selected financial data.
- Operating cash flow remained positive, supported in part by a $56.8 million working-capital source, including a $77.9 million inventory reduction. Operating cash flow less capital expenditures was approximately $35.9 million.
- At year-end, cash was $17.6 million; total debt carrying value was approximately $529.7 million, including $188.0 million of senior subordinated notes classified as short-term and due in 2015. The company reported $302.0 million of unused revolver capacity after covenant restrictions and letters of credit, and stated it was compliant with applicable covenants.
- Total assets were $1,833.8 million and stockholders’ equity was $1,004.5 million. Current assets were $645.0 million versus current liabilities of $351.9 million.
Fourth-quarter results and material changes
Fourth-quarter 2014 net sales were $259.9 million, gross profit was $31.0 million, and net loss was $83.5 million, or $0.61 per diluted share. The quarter included the $75.7 million needle-coke goodwill impairment, a $19.0 million pension and postretirement mark-to-market loss, $5.4 million of rationalization charges and $9.8 million of interest expense. The filing’s extracted quarterly table does not provide a consistently clear fourth-quarter 2013 net-income figure, so a reliable Q4 year-over-year earnings comparison cannot be stated.
Compared with 2013, the company’s annual loss deepened substantially, while sales, gross profit and margins declined. Cost reductions from prior rationalizations began to benefit costs, but lower selling prices and impairment charges more than offset those savings. The workforce decreased by 637 employees during 2014, to 2,397, and graphite-electrode capacity had been reduced by about 60,000 metric tons through facility closures.
Outlook, risks and unusual items
- For the first half of 2015, management targeted EBITDA of $45–$55 million and operating cash flow of approximately $40–$50 million, after $15–$20 million of cash rationalization charges. These are non-GAAP targets and are not guarantees.
- Management expected about $50 million of inventory reduction and $60–$70 million of capital expenditures for full-year 2015. Approximately 60% of targeted 2015 electrode order volumes had been confirmed; booked prices averaged below 2014 year-end pricing. Cost savings were expected to be largely offset by lower pricing.
- Management expected lower oil prices to help needle-coke and electrode input costs, with lower electrode operating rates likely to offset much of the benefit near term. It also expected continued pressure in Engineered Solutions pricing.
- Principal risks include cyclical steel and EAF demand, intense electrode price competition and excess capacity, raw-material and energy availability and pricing, foreign-exchange exposure, covenant and refinancing risk, and the 2015 maturity of the $200 million face-value subordinated notes. The company identified a requirement to maintain at least $300 million of defined liquidity after August 30, 2015 if those notes were not repaid or refinanced by then.
- The $73.4 million increase in the U.S. deferred-tax valuation allowance was non-cash and reflected uncertainty about realizing U.S. tax assets following recent losses. Subsequent to year-end, the company reported a February 2015 credit-agreement amendment, including a new $40 million delayed-draw term loan intended for repayment of the subordinated notes, and anticipated up to $10 million of additional AGM rationalization charges.
- Legal matters disclosed include a Brazilian antitrust investigation and potential claims relating to historical wage provisions. The company said it believed the matters would not have a material adverse effect, while noting that outcomes could not be predicted.
Important facts for investors to verify
- Whether 2015 operating cash flow, EBITDA and inventory-reduction targets were achieved, and whether savings outweighed continued price declines.
- How the $200 million face-value subordinated notes were repaid or refinanced and whether liquidity and revolving-credit covenants remained compliant.
- Whether needle-coke and graphite-electrode demand, pricing and utilization improved, and whether further goodwill or asset impairments were recorded.
- Whether the customer bankruptcy affected future advanced graphite materials sales and whether Engineered Solutions margins recovered.
- Potential outcomes and financial exposure from the Brazilian antitrust investigation, wage litigation risk, environmental matters and deferred-tax-asset realizability.